Literature DB >> 29888204

Management of Hepatocellular Carcinoma in Japan as a World-Leading Model.

Masatoshi Kudo1.   

Abstract

Entities:  

Year:  2017        PMID： 29888204      PMCID： PMC5985410          DOI： 10.1159/000484619

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  41 in total

1.  Japan's Successful Model of Nationwide Hepatocellular Carcinoma Surveillance Highlighting the Urgent Need for Global Surveillance.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

2.  Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines).

Authors:  Norihiro Kokudo; Kiyoshi Hasegawa; Masaaki Akahane; Hiroshi Igaki; Namiki Izumi; Takafumi Ichida; Shinji Uemoto; Shuichi Kaneko; Seiji Kawasaki; Yonson Ku; Masatoshi Kudo; Shoji Kubo; Tadatoshi Takayama; Ryosuke Tateishi; Takashi Fukuda; Osamu Matsui; Yutaka Matsuyama; Takamichi Murakami; Shigeki Arii; Masatoshi Okazaki; Masatoshi Makuuchi
Journal:  Hepatol Res       Date:  2015-01       Impact factor: 4.288

3.  Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis.

Authors:  Satoshi Kitai; Masatoshi Kudo; Naoshi Nishida; Namiki Izumi; Michiie Sakamoto; Yutaka Matsuyama; Takafumi Ichida; Osamu Nakashima; Osamu Matsui; Yonson Ku; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Liver Cancer       Date:  2016-05-03       Impact factor: 11.740

4.  Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan.

Authors:  Masatoshi Kudo; Namiki Izumi; Michiie Sakamoto; Yutaka Matsuyama; Takafumi Ichida; Osamu Nakashima; Osamu Matsui; Yonson Ku; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Liver Cancer       Date:  2016-05-10       Impact factor: 11.740

5.  Treatment of hepatocellular carcinoma with Child-Pugh C cirrhosis.

Authors:  Kazuhiro Nouso; Norihiro Kokudo; Masatoshi Tanaka; Ryoko Kuromatsu; Hiroki Nishikawa; Hidenori Toyoda; Naoki Oishi; Kenji Kuwaki; Masashi Kusanaga; Takuki Sakaguchi; Zenichi Morise; Satoshi Kitai; Masatoshi Kudo
Journal:  Oncology       Date:  2014-11-22       Impact factor: 2.935

6.  Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma.

Authors:  T Seki; M Wakabayashi; T Nakagawa; T Itho; T Shiro; K Kunieda; M Sato; S Uchiyama; K Inoue
Journal:  Cancer       Date:  1994-08-01       Impact factor: 6.860

Review 7.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

8.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors:  Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

9.  Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Deng-Yn Lin; Joong-Won Park; Masatoshi Kudo; Shukui Qin; Hyun-Cheol Chung; Xiangqun Song; Jianming Xu; Guido Poggi; Masao Omata; Susan Pitman Lowenthal; Silvana Lanzalone; Liqiang Yang; Maria Jose Lechuga; Eric Raymond
Journal:  J Clin Oncol       Date:  2013-09-30       Impact factor: 44.544

10.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598
View more
  19 in total

Review 1.  Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.

Authors:  Shiv K Sarin; Manoj Kumar; Mohammed Eslam; Jacob George; Mamun Al Mahtab; Sheikh M Fazle Akbar; Jidong Jia; Qiuju Tian; Rakesh Aggarwal; David H Muljono; Masao Omata; Yoshihiko Ooka; Kwang-Hyub Han; Hye Won Lee; Wasim Jafri; Amna S Butt; Chern H Chong; Seng G Lim; Raoh-Fang Pwu; Ding-Shinn Chen
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-12-15

2.  Surveillance of hepatocellular cancer-why can't we do better?

Authors:  Linda L Wong
Journal:  Hepatobiliary Surg Nutr       Date:  2019-12       Impact factor: 7.293

Review 3.  Ultrasound fusion imaging technologies for guidance in ablation therapy for liver cancer.

Authors:  Yasunori Minami; Masatoshi Kudo
Journal:  J Med Ultrason (2001)       Date:  2020-02-08       Impact factor: 1.314

4.  Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies.

Authors:  Kazuya Kariyama; Kazuhiro Nouso; Akiko Wakuta; Ayano Oonishi; Hidenori Toyoda; Toshifumi Tada; Atsushi Hiraoka; Kunihiko Tsuji; Ei Itobayashi; Toru Ishikawa; Koichi Takaguchi; Akemi Tsutsui; Noritomo Shimada; Takashi Kumada
Journal:  Liver Cancer       Date:  2019-10-22       Impact factor: 11.740

5.  Digestive cancer screening across Europe.

Authors:  Patrizia Burra; Michael Bretthauer; Maria Buti Ferret; Ana Dugic; Pierluigi Fracasso; Marcis Leja; Tamara Matysiak Budnik; Patrick Michl; Luigi Ricciardiello; Thomas Seufferlein; Monique van Leerdam; Andreea Botos
Journal:  United European Gastroenterol J       Date:  2022-04-26       Impact factor: 6.866

6.  B-Mode Ultrasonography versus Contrast-Enhanced Ultrasonography for Surveillance of Hepatocellular Carcinoma: A Prospective Multicenter Randomized Controlled Trial.

Authors:  Masatoshi Kudo; Kazuomi Ueshima; Yukio Osaki; Masashi Hirooka; Yasuharu Imai; Kazunobu Aso; Kazushi Numata; Masayuki Kitano; Takashi Kumada; Namiki Izumi; Yasukiyo Sumino; Chikara Ogawa; Kohei Akazawa
Journal:  Liver Cancer       Date:  2019-06-06       Impact factor: 11.740

Review 7.  A global view of hepatocellular carcinoma: trends, risk, prevention and management.

Authors:  Ju Dong Yang; Pierre Hainaut; Gregory J Gores; Amina Amadou; Amelie Plymoth; Lewis R Roberts
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08-22       Impact factor: 73.082

8.  Trends in Global, Regional, and National Burden and Quality of Care Index for Liver Cancer by Cause from Global Burden of Disease 1990-2019.

Authors:  Seyyed-Hadi Ghamari; Moein Yoosefi; Mohsen Abbasi-Kangevari; Mohammad-Reza Malekpour; Sahar Saeedi Moghaddam; Sarvenaz Shahin; Zahra Esfahani; Sogol Koolaji; Parnian Shobeiri; Aydin Ghaffari; Hanye Sohrabi; Ameneh Kazemi; Negar Rezaei; Bagher Larijani; Farshad Farzadfar
Journal:  Hepatol Commun       Date:  2022-02-08

Review 9.  Liver damage related to immune checkpoint inhibitors.

Authors:  Naoshi Nishida; Masatoshi Kudo
Journal:  Hepatol Int       Date:  2019-01-03       Impact factor: 9.029

10.  Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan.

Authors:  Masatoshi Kudo; Namiki Izumi; Shoji Kubo; Norihiro Kokudo; Michiie Sakamoto; Shuichiro Shiina; Ryosuke Tateishi; Osamu Nakashima; Takamichi Murakami; Yutaka Matsuyama; Arata Takahashi; Hiroaki Miyata; Tadatoshi Takayama
Journal:  Hepatol Res       Date:  2020-01-05       Impact factor: 4.288
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.